Sexual functions and prolactin levels in patients with bipolar disorder

• Main Authors: Rabia Nazik Yuksel, Elif Tatlidil Yaylaci, Hasan Kaya, Gamze Erzin, Emine Merve Akdag, Adem Demirci, Cigdem Aydemir, Erol Goka
• Format: Article
• Language: English
• Published: ANP Publishing 2019-02-01
• Series: Klinik Psikiyatri Dergisi
• Subjects: : Bipolar disorder; mood disorders; sexual dysfunction; sexual disorders; sexual functions; golombok rust inventory of sexual satisfaction
• Online Access: https://www.journalagent.com/kpd/pdfs/KPD_22_1_48_56.pdf
• ISSN: 1302-0099; 2146-7153

Objective: Mood stabilizers and antipsychotic drugs are known to have adverse effects on sexual function. However, patients often refrain from speaking about sexual complaints that may cause dose reduction and discontinuation of the drug without medical supervision. In this study we aimed to evaluate sexual functions of patients with bipolar disorder in remission period, considering prolactin levels and medications. Method: We recruited 52 patients with bipolar disorder in remission according to DSM-IV diagnostic criteria. Prolactin levels were measured in all patients. The Golombok Rust Inventory of Sexual Satisfaction (GRISS) was used to assess sexual dysfunction. Results: Mean prolactin levels were 24.71 ± 4.25 and 19.96 ± 5.52 ng/ml respectively for females and males. Patients taking mood stabilizer (MS) and mood stabilizer plus antipsychotic (AP) treatment had different prolactin levels (p<0.001). Total GRISS scores were not different for MS and MS+AP treatment groups. We didn't find a correlation between Total GRISS scores and prolactin levels. There was a significant deterioration in female non-sensuality, female dissatisfaction and anorgasmia subscales of female patients and significant deterioration in premature ejaculation, impotence and male dissatisfaction subscales of male patients. Discussion: In our sample, both men and women patients with bipolar disorder in remission have sexual dysfunctions. Our results suggest that prolactin levels are not sufficient to demonstrate the sexual dysfunction. To enhance patient compliance it is necessary to focus more on sexual symptoms of patients receiving MS and AP treatment.